| Literature DB >> 26741962 |
Demetrio L Valle1, Esperanza C Cabrera2, Juliana Janet M Puzon3, Windell L Rivera3.
Abstract
Piper betle L. has traditionally been used in alternative medicine in different countries for various therapeutic purposes, including as an anti-infective agent. However, studies reported in the literature are mainly on its activities on drug susceptible bacterial strains. This study determined the antimicrobial activities of its ethanol, methanol, and supercritical CO2 extracts on clinical isolates of multiple drug resistant bacteria which have been identified by the Infectious Disease Society of America as among the currently more challenging strains in clinical management. Assay methods included the standard disc diffusion method and the broth microdilution method for the determination of the minimum inhibitory concentration (MIC) and the minimum bactericidal concentrations (MBC) of the extracts for the test microorganisms. This study revealed the bactericidal activities of all the P. betle leaf crude extracts on methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), extended spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and metallo-β-lactamase-producing Pseudomonas aeruginosa and Acinetobacter baumannii, with minimum bactericidal concentrations that ranged from 19μg/ml to 1250 μg/ml. The extracts proved to be more potent against the Gram positive MRSA and VRE than for the Gram negative test bacteria. VRE isolates were more susceptible to all the extracts than the MRSA isolates. Generally, the ethanol extracts proved to be more potent than the methanol extracts and supercritical CO2 extracts as shown by their lower MICs for both the Gram positive and Gram negative MDRs. MTT cytotoxicity assay showed that the highest concentration (100 μg/ml) of P. betle ethanol extract tested was not toxic to normal human dermal fibroblasts (HDFn). Data from the study firmly established P. betle as an alternative source of anti-infectives against multiple drug resistant bacteria.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26741962 PMCID: PMC4704777 DOI: 10.1371/journal.pone.0146349
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Panel of MDR clinical bacterial strains used in in vitro antibacterial testing with Piper betle extracts.
| MDR Bacterial Strain | Source | Resistance phenotype |
|---|---|---|
| MRSA 1 | 12/Male, Wound | SXT, FOX, OX, P |
| MRSA 2 | 69/M, Wound | FOX, OX, P |
| MRSA 3 | 42/M, Blood | SXT, FOX, OX, P |
| MRSA 4 | 35/F, Sputum | SXT, FOX, OX, P |
| MRSA 5 | 45/M, Wound | FOX, OX, P |
| MRSA 6 | 65/F, Wound | SXT, FOX, OX, P |
| MRSA 7 | 34/F, Nipple discharge | FOX, OX, P |
| VRE 1 | 45/M, Urine | AM, P, VA |
| VRE 2 | 24/F, Peritoneal fluid | AM, P, VA |
| VRE 3 | 33/F, Urine | AM, P, VA |
| 31/M, Urine | AM, FEP, CTX, CTZ, CRP | |
| 25/F, Urine | AM, FEP, CTX, CTZ, CRP | |
| 43/M, Blood | AM, FEP, CL, CTZ, CRO, IPM, MEM | |
| 75/F, Sputum | AK, AM, FEP, CTZ, CRO, IPM, MEM | |
| 52/M, Urine | AK, FEP, CTZ, CTZ, CRO, IPM, MEM | |
| 59/F, Blood | AM, CL, FEP, CTZ, CRO, IPM, MEM | |
| 75/F, Blood | AM, CL, FEP, CTZ, CRO, IPM, MEM | |
| 64,M, Blood | AK, FEP, CTZ, IPM, MEM | |
| 75/F, Wound | FEP, CTZ, IPM, LVX, MEM | |
| 42/F, Blood | AK, CTZ, IPM, LVX, MEM | |
| 53/F, Blood | AK, CTZ, IPM, LVX, MEM | |
| 48/M, Urine | CTZ, IPM, LVX, MEM | |
| 64/F, Blood | AK, CTZ, IPM, LVX, MEM | |
| 58/F, Sputum | CTZ, IPM, LVX, MEM | |
| 76/F, Blood | AK, CTZ, IPM, LVX,MEM |
MDR bacterial strains: CRE- carbapenem-resistant Enterobacteriaceae, ESβL- extended spectrum β- lactamase, MβL- metallo β-lactamase, MRSA- methicillin resistant Staphylococcus aureus, VRE- vancomycin resistant enterococci
Antimicrobial agents: AK- amikacin, AM- ampicillin, CL- colistin, CRO- ceftriaxone, CTX- cefotaxime, CTZ- ceftazidime, FEP- cefepime, FOX- cefoxitin, IPM- imipenem, LVX- levofloxacin, MEM- meropenem, OX- oxacillin, P–penicillin, SXT- Trimethoprim-sulfamethoxazole, VA- vancomycin
Diameters of zones of inhibition (mm)* of Piper betle extracts against multidrug-resistant bacteria.
| MDR bacterial strains | Ethanol Extract | Methanol Extract | SC-CO2 15MPa | SC-CO2 20Mpa |
|---|---|---|---|---|
| MRSA 1 | 33 | 32 | 25 | 25 |
| MRSA 2 | 34 | 32 | 27 | 28 |
| MRSA 3 | 28 | 26 | 21 | 22 |
| MRSA 4 | 34 | 33 | 27 | 30 |
| MRSA 5 | 38 | 34 | 30 | 33 |
| MRSA 6 | 29 | 28 | 23 | 23 |
| MRSA 7 | 30 | 28 | 23 | 27 |
| VRE 1 | 28 | 26 | 20 | 24 |
| VRE 2 | 25 | 25 | 15 | 15 |
| VRE 3 | 32 | 32 | 28 | 31 |
| 20 | 19 | 15 | 16 | |
| 20 | 19 | 15 | 16 | |
| 21 | 21 | 15 | 16 | |
| 24 | 23 | 20 | 20 | |
| 23 | 22 | 16 | 17 | |
| 23 | 22 | 16 | 17 | |
| 20 | 19 | 18 | 18 | |
| 17 | 15 | 11 | 11 | |
| 19 | 18 | 14 | 15 | |
| 28 | 27 | 12 | 14 | |
| 23 | 22 | 20 | 22 | |
| 24 | 24 | 20 | 22 | |
| 24 | 23 | 19 | 22 | |
| 23 | 22 | 18 | 21 | |
| 26 | 25 | 21 | 24 |
MDR bacterial strains: CRE- carbapenem-resistant Enterobacteriaceae, ESβL- extended spectrum β- lactamase, MβL- metallo β-lactamase, MRSA- methicillin resistant Staphylococcus aureus, VRE- vancomycin resistant enterococci
SC-CO2 –supercritical carbon dioxide
*Zone size includes 6 mm disk
Fig 1Representative plates for disc diffusion assay showing zones of inhibition produced by Piper betle ethanol, methanol, SC-CO2 15 MPA and SC-CO2 20 MPa extracts on multiple drug resistant clinical bacterial isolates, with the corresponding reference antibiotic discs.
A. Methicillin resistant Staphylococcus aureus or MRSA 5; B. Vancomycin resistant Enterococcus 3; C. Pseudomonas aeruginosa metallo β lactamase or MβL (+) 3; D. Klebsiella pneumoniae carbapenem resistant Enterobacteriaceae 3; E. MRSA 1; F. Acinetobacter baumannii MβL (+) 1.
Minimum inhibitory concentrations (μg/ml) of Piper betle extracts for multidrug-resistant bacteria.
| MDR bacterial strains | Ethanol Extract | Methanol Extract | SC-CO2 15MPa | SC-CO2 20Mpa |
|---|---|---|---|---|
| MRSA 1 | 156 | 156 | 625 | 625 |
| MRSA 2 | 156 | 156 | 625 | 625 |
| MRSA 3 | 156 | 156 | 312 | 312 |
| MRSA 4 | 78 | 156 | 312 | 312 |
| MRSA 5 | 78 | 78 | 312 | 312 |
| MRSA 6 | 156 | 312 | 625 | 625 |
| MRSA 7 | 78 | 156 | 312 | 156 |
| VRE 1 | 19 | 19 | 19 | 19 |
| VRE 2 | 19 | 19 | 19 | 19 |
| VRE 3 | 156 | 156 | 156 | 156 |
| 312 | 312 | 625 | 625 | |
| 625 | 625 | 1250 | 625 | |
| 312 | 625 | 625 | 312 | |
| 312 | 312 | 625 | 312 | |
| 625 | 625 | 625 | 625 | |
| 312 | 312 | 625 | 312 | |
| 312 | 312 | 312 | 312 | |
| 312 | 625 | 1250 | 625 | |
| 312 | 625 | 1250 | 625 | |
| 156 | 156 | 625 | 625 | |
| 625 | 625 | 625 | 625 | |
| 156 | 625 | 625 | 312 | |
| 312 | 625 | 625 | 625 | |
| 312 | 312 | 625 | 312 | |
| 625 | 625 | 625 | 625 |
MDR bacterial strains: CRE- carbapenem-resistant Enterobacteriaceae, ESβL- extended spectrum β- lactamase, MβL- metallo β-lactamase, MRSA- methicillin resistant Staphylococcus aureus, VRE- vancomycin resistant enterococci
SC-CO2 –supercritical carbon dioxide
Minimum bactericidal concentration (μg/mL) of Piper betle extracts against multidrug-resistant bacteria.
| MDR bacterial strains | Ethanol Extract | Methanol Extract | SC-CO2 15MPa | SC-CO2 20Mpa |
|---|---|---|---|---|
| MRSA 1 | 312 | 312 | 1250 | 625 |
| MRSA 2 | 156 | 312 | 625 | 625 |
| MRSA 3 | 156 | 156 | 312 | 312 |
| MRSA 4 | 78 | 156 | 312 | 312 |
| MRSA 5 | 78 | 78 | 312 | 312 |
| MRSA 6 | 156 | 312 | 625 | 625 |
| MRSA 7 | 78 | 156 | 312 | 156 |
| VRE 1 | 19 | 19 | 19 | 19 |
| VRE 2 | 19 | 19 | 19 | 19 |
| VRE 3 | 156 | 156 | 156 | 156 |
| 312 | 312 | 1250 | 625 | |
| 625 | 625 | 1250 | 625 | |
| 312 | 625 | 625 | 312 | |
| 312 | 312 | 1250 | 625 | |
| 625 | 625 | 1250 | 625 | |
| 312 | 312 | 625 | 312 | |
| 312 | 312 | 312 | 312 | |
| 312 | 625 | 1250 | 625 | |
| 312 | 625 | 1250 | 625 | |
| 156 | 156 | 625 | 625 | |
| 625 | 625 | 625 | 625 | |
| 312 | 1250 | 1250 | 625 | |
| 312 | 625 | 625 | 625 | |
| 312 | 312 | 625 | 312 | |
| 625 | 625 | 625 | 625 |
MDR bacterial strains: CRE- carbapenem-resistant Enterobacteriaceae, ESβL- extended spectrum β- lactamase, MβL- metallo β-lactamase, MRSA- methicillin resistant Staphylococcus aureus, VRE- vancomycin resistant enterococci
SC-CO2 –supercritical carbon dioxide
Cytotoxicity index (CI%) of Piper betle (or Ikmo) ethanol extract on normal human dermal fibroblasts (HDFn) using the MTT cytotoxicity assay.
| ug/mL | Doxorubicin | DMSO | Untreated | |
|---|---|---|---|---|
| 100 | 84.84241 | 45.758183 | 28.22008 | 11.45928 |
| 50 | 76.36485 | 41.3372199 | 16.99763 | 12.84387 |
| 25 | 68.17878 | 35.0215583 | 15.51588 | -3.77118 |
| 12.5 | 58.02514 | 32.5438756 | 11.55645 | 0.236837 |
| 6.25 | 52.4625 | 28.7058966 | 6.892573 | 11.24066 |
| 3.125 | 46.99702 | 24.7464626 | 0.79553 | -29.714 |
| 1.56 | 37.8879 | 17.7749438 | -16.9855 | -19.8761 |
| 0.78 | 16.36607 | 7.98566831 | -27.7464 | 17.58062 |
Positive Control: Doxorubicin
Negative control: DMSO and Untreated (no extract, no DMSO were added to the wells with HDFn)
Fig 2Cytotoxicity index (CI%) of Piper betle (or “Ikmo”) ethanol extract on normal human dermal fibroblasts (HDFn) using the MTT cytotoxicity assay.
The CI% of the highest concentration tested (100μg/ml) is below the IC50 value, indicating nontoxicity to the cells. Positive control: Doxorubicin; Negative controls: DMSO and UnTx (untreated- no DMSO, no P. betle extract were added to the wells with HDFn).
Fig 3MTT cytotoxicity results for Piper betle ethanol extract.
Positive control: Doxorubicin; Negative controls: DMSO and untreated (no DMSO, no P. betle extract were added to the wells with HDFn). Each treatment was done in triplicate.